What causes dba
Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.
Last updated: April 4, 2026
Key Facts
- DBA affects approximately 1 in 100,000 newborns.
- It is an inherited condition, with about 90% of cases being caused by mutations in ribosomal protein genes.
- The most common mutation associated with DBA occurs in the RPS19 gene, accounting for about 25% of cases.
- Symptoms typically appear within the first year of life, with most infants diagnosed by 6 months.
- DBA is a lifelong condition requiring ongoing medical management.
What is Diamond-Blackfan Anemia (DBA)?
Diamond-Blackfan Anemia (DBA) is a rare, inherited disorder characterized by the bone marrow's inability to produce sufficient red blood cells. This leads to a severe form of anemia, meaning the body doesn't have enough healthy red blood cells to carry adequate oxygen to its tissues. DBA is considered a bone marrow failure syndrome, specifically affecting erythropoiesis, the process of red blood cell production.
What Causes DBA?
The primary cause of DBA is genetic mutations. In most cases (around 90%), these mutations occur in genes responsible for producing ribosomal proteins. Ribosomes are essential cellular machinery responsible for protein synthesis. When these genes are mutated, the production of functional ribosomes is impaired, which disproportionately affects rapidly dividing cells, such as those in the bone marrow that are responsible for creating red blood cells. This leads to a selective failure of erythropoiesis.
Genetic Basis of DBA
Over a dozen different genes have been linked to DBA, with mutations in genes coding for ribosomal proteins being the most common. The RPS19 gene is the most frequently implicated, found in about 25% of DBA patients. Other commonly affected genes include RPS24, RPS17, RPL5, and RPL11. While most cases are inherited, about 10% of DBA cases may arise from spontaneous genetic mutations (de novo mutations) that occur during conception or early development.
The inheritance pattern for DBA is typically autosomal dominant. This means that a person needs only one copy of the mutated gene from either parent to develop the condition. However, the severity of DBA can vary significantly even within the same family. Some individuals may have milder symptoms, while others experience more severe disease.
Symptoms and Diagnosis
The hallmark symptom of DBA is severe anemia, which usually becomes apparent within the first few months of a baby's life. Infants with DBA may exhibit:
- Pale skin
- Lethargy or fatigue
- Poor feeding
- Rapid heartbeat
- Shortness of breath
Beyond anemia, DBA can be associated with a range of physical abnormalities. These can include:
- Distinctive facial features (e.g., broad nasal bridge, low-set ears, downturned mouth)
- Congenital malformations of the upper limbs (e.g., thumb abnormalities, missing fingers, shortened arms)
- Heart defects
- Genitourinary abnormalities
- Growth delays
Diagnosis is typically made through a combination of clinical evaluation, blood tests (revealing severe anemia with a normal number of white blood cells and platelets, and elevated levels of fetal hemoglobin), and bone marrow examination. Genetic testing can confirm the diagnosis by identifying mutations in DBA-associated genes.
Treatment and Management
DBA is a chronic condition that requires lifelong management. The primary treatment goal is to increase red blood cell counts and manage symptoms.
- Corticosteroids: These are often the first-line treatment and can stimulate red blood cell production in many patients. However, long-term steroid use can lead to significant side effects.
- Blood Transfusions: For patients who do not respond adequately to steroids or cannot tolerate them, regular blood transfusions are necessary to maintain adequate hemoglobin levels.
- Stem Cell Transplantation: In severe cases, or for patients who become refractory to other treatments, a stem cell transplant (bone marrow transplant) from a matched donor may be considered a curative option.
- Other Therapies: Research is ongoing into novel therapies, including drugs that stimulate red blood cell production (erythropoiesis-stimulating agents) and gene therapy approaches.
Regular monitoring for complications, such as iron overload from transfusions, infections, and the development of secondary cancers, is crucial for individuals with DBA.
Prognosis
The prognosis for DBA varies depending on the severity of the anemia, the presence of associated abnormalities, and the response to treatment. With advancements in medical care, including improved transfusion support, corticosteroid management, and successful stem cell transplants, many individuals with DBA can lead relatively normal lives. However, it remains a serious condition requiring specialized care throughout their lives.
More What Causes in Daily Life
Also in Daily Life
More "What Causes" Questions
Trending on WhatAnswers
Browse by Topic
Browse by Question Type
Sources
Missing an answer?
Suggest a question and we'll generate an answer for it.